Novavax begins mid-stage study of COVID-19 vaccine in South Africa

Novavax begins mid-stage study of COVID-19 vaccine in South Africa The Phase 2b trial study of NVX-CoV2373 will be conducted on about 2,665 healthy adults and will evaluate the safety and immunogenicity in about 240 medically stable, HIV-positive adults, the company said in a statement.

No comments:

Post a Comment